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BACKGROUND Primary percutaneous coronary intervention (pPCI) is
currently the most effective treatment strategy in ST-segment eleva-
tion acute myocardial infarction (STEMI). A considerable number of
patients, however, develop no-reﬂow phenomenon during pPCI.
Compared to similar patients with adequate reﬂow, those with the no-
reﬂow phenomenon have a higher incidence of death, myocardial
infarction and heart failure. No-reﬂow is considered a dynamic pro-
cess characterized by multiple pathogenetic components including
distal atherothrombotic embolization, ischemic injury, reperfusion
injury, and susceptibility of coronary microcirculation to injury, and
current treatments are limited. We have established a risk prediction
model of no-reﬂow in our previous studies, [8,9] through which we
were able to ﬁnd out patients at high risk of no-reﬂow. The aim of this
study was to investigate the effectiveness of a combination therapy
for the prevention of no-reﬂow in patient with STEMI undergoing
primary PCI.
METHODS A total of 621 patients with STEMI who underwent emer-
gency primary PCI were enrolled in this study. Patients with high risk
of no-reﬂow (no-ﬂow score  10, by using a no-ﬂow risk prediction
model n ¼ 216) were randomly divided into control group (n ¼ 108)
and combination therapy group (n ¼ 108). Patients in control group
received conventional treatment, while patients in combination
therapy group received high-dose (80 mg) atorvastatin pre-treatment,
intracoronary administration of adenosine (140 mg/min/kg) during PCI
procedure, platelet membrane glycoprotein IIb/IIIa receptor antago-
nist (tiroﬁban, 10 mg/kg bolus followed by 0.15 mg/kg/min) and
thrombus aspiration. Myocardial contrast echocardiography (MCE;
SonoVue; Bracco) was performed to assess the myocardial perfusion
72 hours after PCI. Major adverse cardiac events (MACE) were fol-
lowed up for six months.
RESULTS A total of 1217 patients were admitted to our hospital during
the enrolment for AMI; 962 (79%) were considered to have STEMI by
12-leads electrocardiography and 769 had no documented or self-
reported prior AMI. Of the ﬁrst STEMI, 17 died and 15 were transferred
to other hospitals before a decision on whether or not to undergo PCI
was made. Sixty-four were excluded due to contraindications to
reperfusion and 41 patients refused to participate in this study.
Finally, 621 patients were enrolled (Figure 1), Among which 216
(34.8%) high risk patients of no-reﬂow were selected by no-reﬂow risk
prediction model. [8,9] Patients demographics, angiography and
procedural data examined in different group are shown in Table 2.
No-reﬂow occurred in 11 cases (11/405, 2.7%) in low risk patients, 38
cases (38/108, 35.2%) in control group and 3 cases (2.8%) in combi-
nation therapy group. (Figure 2).
MCE at 72 hours after PCI procedure suggested a higher A  b value
in combination therapy group than that of control group (Figure 3, 4).
Six months clinical follow-up was obtained in 552 patients. Events
rates are presented in Table 3. There were 6 (6.3%) events (1 death, 2
non-fatal MIs and 3 revascularizations) in combination therapy group,
signiﬁcantly lower than 12 (13.2%) events (4 deaths, 3 non-fatal MIs
and 5 revascularizations) in control group.CONCLUSION Our study discovered that using no-ﬂow risk prediction
model to screen AMI patients who had been suffered with high risk of
no-reﬂow, and pre-treated them with combination treatment could
signiﬁcantly lower the incidence of no-reﬂow, and further improved
the prognosis. MACE happened in combination treatment group
decreased by 55% compared with control group.
